Targeting MCM6 Enhances Melphalan Chemosensitivity in Retinoblastoma by Modulating DNA Damage Response

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Retinoblastoma is a pediatric eye cancer with limited treatment options.
• Melphalan is a standard chemotherapy agent, but resistance is a challenge.
• Understanding molecular drivers of retinoblastoma progression and drug resistance is crucial.

Purpose of the Study:

• To investigate the role of minichromosome maintenance complex component 6 (MCM6) in retinoblastoma.
• To determine MCM6's impact on retinoblastoma progression.
• To assess MCM6's influence on melphalan chemosensitivity.

Main Methods:

• Single-cell RNA sequencing (scRNA-seq) of retinoblastoma.
• Validation in patient tumor specimens, including post-therapy samples.
• MCM6 knockdown cell lines for functional assays and in vivo xenograft models.

Main Results:

• MCM6 is highly expressed in retinoblastoma, linked to proliferation.
• Elevated MCM6 expression correlates with melphalan treatment failure.
• MCM6 knockdown reduced proliferation, increased DNA damage, and sensitized cells to melphalan.

Conclusions:

• MCM6 is a key regulator of retinoblastoma growth and melphalan response.
• Targeting MCM6 may overcome melphalan resistance in retinoblastoma.
• MCM6 inhibition offers a potential therapeutic strategy to improve retinoblastoma treatment outcomes.